IS5275A - Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti - Google Patents

Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti

Info

Publication number
IS5275A
IS5275A IS5275A IS5275A IS5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A
Authority
IS
Iceland
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretion
secretion
Prior art date
Application number
IS5275A
Other languages
English (en)
Icelandic (is)
Inventor
Albert Carpino Philip
Kwok-Fung Chiu Charles
Allen Lefker Bruce
Codetta Pan Lydia
Lee Treadway Judith
Paul Zawistoski Michael
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5275A publication Critical patent/IS5275A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IS5275A 1997-06-25 1999-11-26 Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti IS5275A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IS5275A true IS5275A (is) 1999-11-26

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5275A IS5275A (is) 1997-06-25 1999-11-26 Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti

Country Status (40)

Country Link
US (3) US6448263B1 (OSRAM)
EP (1) EP1000085B1 (OSRAM)
JP (2) JP2000514099A (OSRAM)
KR (1) KR20010014224A (OSRAM)
CN (2) CN1152049C (OSRAM)
AP (1) AP1145A (OSRAM)
AR (1) AR012256A1 (OSRAM)
AT (1) ATE305477T1 (OSRAM)
AU (1) AU747510B2 (OSRAM)
BG (1) BG104008A (OSRAM)
BR (1) BR9810477A (OSRAM)
CA (1) CA2294464A1 (OSRAM)
CO (1) CO4950621A1 (OSRAM)
DE (1) DE69831745T2 (OSRAM)
DZ (1) DZ2539A1 (OSRAM)
EA (1) EA002089B1 (OSRAM)
EG (1) EG21712A (OSRAM)
ES (1) ES2248899T3 (OSRAM)
HN (1) HN1998000088A (OSRAM)
HR (1) HRP980361A2 (OSRAM)
HU (1) HUP0001922A3 (OSRAM)
ID (1) ID24345A (OSRAM)
IL (7) IL154116A0 (OSRAM)
IN (1) IN189724B (OSRAM)
IS (1) IS5275A (OSRAM)
MA (1) MA24581A1 (OSRAM)
NO (1) NO996205D0 (OSRAM)
NZ (1) NZ500655A (OSRAM)
OA (1) OA11242A (OSRAM)
PA (1) PA8452601A1 (OSRAM)
PE (1) PE105399A1 (OSRAM)
PL (1) PL337659A1 (OSRAM)
SK (1) SK175699A3 (OSRAM)
TN (1) TNSN98113A1 (OSRAM)
TR (1) TR199903257T2 (OSRAM)
TW (1) TW553943B (OSRAM)
UA (1) UA64751C2 (OSRAM)
WO (1) WO1998058949A1 (OSRAM)
YU (1) YU70199A (OSRAM)
ZA (1) ZA985546B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
AU2005319393B2 (en) * 2004-12-21 2010-09-02 Solenis Technologies Cayman, L.P. Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
PE20142443A1 (es) 2012-05-03 2015-01-28 Novartis Ag Sal de l-malato de derivados de 2,7-diaza-espiro[4,5]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de grelina
ES2678020T3 (es) * 2013-05-28 2018-08-08 Raqualia Pharma Inc. Formas polimórficas
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
EP3212648A1 (en) * 2014-10-31 2017-09-06 RaQualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
CZ151495A3 (en) 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
WO1997023508A1 (en) 1995-12-22 1997-07-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
USRE38524E1 (en) * 1997-06-25 2004-06-01 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
KR20010014224A (ko) 2001-02-26
IL154115A0 (en) 2003-07-31
CA2294464A1 (en) 1998-12-30
IL154114A0 (en) 2003-07-31
YU70199A (sh) 2003-01-31
ID24345A (id) 2000-07-13
SK175699A3 (en) 2001-04-09
CN1259140A (zh) 2000-07-05
EP1000085B1 (en) 2005-09-28
BR9810477A (pt) 2007-05-22
TW553943B (en) 2003-09-21
MA24581A1 (fr) 1998-12-31
CN1152049C (zh) 2004-06-02
HN1998000088A (es) 1999-01-08
US6448263B1 (en) 2002-09-10
AU7445698A (en) 1999-01-04
HK1028051A1 (en) 2001-02-02
IL154116A0 (en) 2003-07-31
PL337659A1 (en) 2000-08-28
HUP0001922A3 (en) 2001-02-28
AP1145A (en) 2003-02-14
DE69831745T2 (de) 2006-08-31
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
DZ2539A1 (fr) 2003-02-08
ATE305477T1 (de) 2005-10-15
CO4950621A1 (es) 2000-09-01
WO1998058949A1 (en) 1998-12-30
US6630487B2 (en) 2003-10-07
JP2000514099A (ja) 2000-10-24
IL156465A0 (en) 2004-01-04
NO996205L (no) 1999-12-15
HRP980361A2 (en) 1999-02-28
US6867202B1 (en) 2005-03-15
AR012256A1 (es) 2000-09-27
PA8452601A1 (es) 2000-05-24
BG104008A (en) 2000-07-31
EA002089B1 (ru) 2001-12-24
IN189724B (OSRAM) 2003-04-19
IL156465A (en) 2004-07-25
ZA985546B (en) 2000-01-10
NO996205D0 (no) 1999-12-15
IL154111A0 (en) 2003-07-31
DE69831745D1 (de) 2006-02-09
TR199903257T2 (xx) 2000-12-21
EG21712A (en) 2002-02-27
OA11242A (en) 2003-07-23
UA64751C2 (uk) 2004-03-15
CN1530107A (zh) 2004-09-22
EA199901075A1 (ru) 2000-08-28
JP2005097261A (ja) 2005-04-14
US20030100561A1 (en) 2003-05-29
NZ500655A (en) 2002-02-01
AU747510B2 (en) 2002-05-16
PE105399A1 (es) 1999-11-04
EP1000085A1 (en) 2000-05-17
ES2248899T3 (es) 2006-03-16
JP3742643B2 (ja) 2006-02-08
TNSN98113A1 (fr) 2005-03-15
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
IS5275A (is) Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti
DE69531573D1 (de) Implantierbare rohrförmige Prothese mit Manschetten
DE69938295D1 (de) Kleinlumiges biologisches transplantat mit therapeutischer verabreichungsvorrichtung
DE69625785D1 (de) Katheter mit Flüssigarzneiinjektor
DE69804533D1 (de) Ballonkatheter mit Impeller zur Blutförderung
FI963482A0 (fi) Menetelmä hematopoieesin stimuloimiseksi hemoglobiinilla
DE69711561D1 (de) Vorgefüllte Spritze
DE69733027D1 (de) Infusionsballonkatheter
DK0925083T3 (da) Engangssprøjte
DE69504241D1 (de) Vorgefüllte Spritze
NO20001242L (no) April - et nytt protein med veksteffekter
DE69618028D1 (de) Medizinische zuleitung mit kompressionslumen
DE69825451D1 (de) Kanüle mit mehreren leitungen
DE122004000049I1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt.
DE69727968D1 (de) Ablations-katheter mit mehreren elektroden
EP0741578A4 (en) HUMAN GROWTH HORMONE
PL338883A1 (en) Growth hormone secretion stimulating compounds
NO973438D0 (no) Insulinderivater med forhöyet sinkbinding
DE69812588D1 (de) Medizinischer injektor
EP0688570A3 (de) Insulinspritze
ZA987383B (en) Treatment of congestive heart failure with growth hormone secretagogues.
NO960485L (no) Selvdestruerende injeksjonsspröyte
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
DE69904407D1 (de) Automatische Insulininjektionsspritze mit Arztmode
DE69318821D1 (de) Katheter zur Versorgung des Penis mit Medikamenten